Show results for
Refine by
Obesity Disorder Articles & Analysis
4 news found
“FDA clearance of our GIBI HD™ calibration tube, which supports bariatric procedures across the spectrum, marks an important addition to our suite of physician led weight loss solutions and we look forward to formally introducing this important new product at the International Federation for the Surgery of Obesity and Metabolic Disorders – IFSO ...
Neurovalens, a global leader of neuro-technology products, is embarking on the development of a device for the treatment of obesity with £1m support from Invest NI. The technology is based on the neuro stimulation of specific areas of the brain responsible for influencing appetite and cravings. The company specialises in combining neuroscience and technology to tackle ...
Camurus (NASDAQ STO: CAMX) today announces that the company’s license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in patients six years of age and older with a rare genetic disease of obesity. “We are pleased with the progress of our collaboration with Rhythm and today’s ...
"In addition to treating Parkinson’s disease, we can also adapt our technology to other disease states being investigated for treatment with DBS such as Alzheimer's disease, depression, epilepsy, obsessive-compulsive disorder, and obesity." About DBI Deep Brain Innovations (DBI) is a medical device company that has developed a proprietary method to ...